1 / 6

U.S. Continuous Glucose Monitoring Systems (CGMS) Market

Rise in adoption of the system, increase in prevalence of diabetes across the U.S., and rise in awareness among people are the key factors that is expected to drive the U.S. continuous glucose monitoring systems market during the forecast period.

newmarketindustry
Download Presentation

U.S. Continuous Glucose Monitoring Systems (CGMS) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. U.S. Continuous Glucose Monitoring Systems (CGMS) Market

  2. Continuous Glucose Monitoring System (CGMS) is an advanced sensor technology used to track glucose level without pricking fingers. It is more effective & accessible for patients with type 2 diabetes (T2D). In it the glucose levels are taken from interstitial fluid. The system takes glucose measurements at regular intervals, 24 hours a day, and generates glucose direction & rate of change. The system involves reusable transmitters that provide real-time reading of glucose monitoring. It can help reduce the risk of hypoglycemia & hyperglycemia, whether users are on pump therapy or insulin injections. According to Centers for Disease Control and Prevention (CDC) report, in 2017, around 30.3 million people suffered from diabetes in the U.S. In September 2017, the FDA approved first CGMS that does not require fingerstick measurement calibration. Get Sample Report

  3. Components of continuous glucose monitoring system include insulin pumps, transmitters & receivers, and sensors. The adult population makes more use of the system compared to children as the number of diabetic patients is more for adults. Rise in adoption of the system, increase in prevalence of diabetes across the U.S., and rise in awareness among people are the key factors that is expected to drive the U.S. continuous glucose monitoring systems market during the forecast period. In addition, surge in need for hypoglycemic & hyperglycemic diagnosis and rise in demand for glucose level testing instantly is expected to boost the market in the coming years.

  4. Moreover, rise in opportunities in the U.S. with the surge in need for R & D by the key players is also expected to boost the growth of the market. However, expensive systems and stringent regulatory policies are the major restraints that are anticipated to hamper the growth of the market during the forecast period. In addition, increase in undiagnosed patient population and rise in product awareness is expected to provide numerous opportunities for the market in the coming years.

  5. KEY BENEFITS FOR STAKEHOLDERS • This report provides a detailed quantitative analysis of the current market trends and market forecast estimations from 2019 to 2026, which assists to identify the prevailing U.S. continuous glucose monitoring systems (CGMS) market opportunities. • An in-depth market analysis includes study of the market and is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate the U.S. plans. • A comprehensive analysis of the factors that drive and restrain the growth of the market is provided in the report. • The projections in this report are made by analyzing the current market trends and future market potential from 2019 to 2026, in terms of value.

  6. The market is segmented on the basis of component, age group, distribution channel, and end user. On the basis of component, it is categorized into insulin pumps, transmitters & receivers, and sensors. On the basis of age group, it is divided into adult and children. On the basis of distribution channel, it is segmented into retail pharmacy and online pharmacy. On the basis of end user, it is divided into hospitals, clinics, homecare diagnostics, and others. Some of the major players operating in the U.S. continuous glucose monitoring systems (CGMS) market include Abbott Laboratories, Pfizer Inc., Baxter International Inc., Echo Therapeutics, Inc., Medtronic plc, F. Hoffmann-La Roche AG, Dexcom Inc., Animas Corporation, Novo Nordisk A/S, and GlySens Incorporated.

More Related